RFP - supply of Recombinant Factor VIII, Recombinant Factor IX and bypassing agents for the treatment of haemophilia
PHARMAC invites proposals for the supply of Recombinant Factor VIII, Recombinant Factor IX and bypassing agents (Recombinant Factor VIIa and FEIBA) in New Zealand.
If you have any questions about this RFP, please post these on the Government Electronic Tenders Service (www.gets.govt.nz(external link)).
Answers to questions will be provided through the Government Electronic Tenders Service (GETS). PHARMAC will also post any addenda through GETS. We encourage interested organisations to register with GETS and subscribe to this RFP to be kept up to date.
This request for proposals (RFP) document incorporates the following schedules:
- Schedule 1 specifies the pharmaceutical for which PHARMAC is requesting proposals and sets out the background to the RFP and the types of proposals sought;
- Schedule 2 describes the process that PHARMAC expects to follow in relation to the RFP;
- Schedule 3 sets out information about the estimated size of the current subsidised market for the pharmaceutical; and
- Schedule 4 contains the RFP form in which you are to provide details of your proposal [DOCX, 41 KB].
Full text of RFP [PDF, 257 KB] - supply of products used for the treatment of haemophilia
PHARMAC standard terms and conditions for the supply of pharmaceuticals [PDF, 79 KB]
If you wish to submit a proposal, you must submit it to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz(external link)) no later than 5:00 pm on Monday, 20 August 2018 - RFx ID 19909881.
If you have any questions about this RFP, please post these on GETS (www.gets.govt.nz(external link)).
We look forward to receiving your proposal.